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Abstract
Background: Drug formularies have been created by third party payers to control prescription
drug usage and manage costs. Physicians try to provide the best care for their patients. This
research examines family physicians' attitudes regarding prescription reimbursement criteria,
prescribing and advocacy for patients experiencing reimbursement barriers.
Methods: Focus groups were used to collect qualitative data on family physicians' prescribing
decisions related to drug reimbursement guidelines. Forty-eight family physicians from four
Ontario cities participated. Ethics approval for this study was received from the Hamilton Health
Sciences/Faculty of Health Sciences Research Ethics Board at McMaster University. Four clinical
scenarios were used to situate and initiate focus group discussions about prescribing decisions.
Open-ended questions were used to probe physicians' experiences and attitudes and responses
were audio recorded. NVivo software was used to assist in data analysis.
Results:  Most physicians reported that drug reimbursement guidelines complicated their
prescribing process and can require lengthy interpretation and advocacy for patients who require
medication that is subject to reimbursement restrictions.
Conclusion: Physicians do not generally see their role as being cost-containment monitors and
observed that cumbersome reimbursement guidelines influence medication choice beyond the
clinical needs of the patient, and produce unequal access to medication. They observed that
frustration, discouragement, fatigue, and lack of appreciation can often contribute to family
physicians' failure to advocate more for patients. Physicians argue cumbersome reimbursement
regulations contribute to lower quality care and misuse of physicians' time increasing overall health
care costs by adding unnecessary visits to family physicians, specialists, and emergency rooms.
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Background
In Canada and elsewhere, in recognition of the fact that
resources for health care (including drugs) are con-
strained, formularies have been established to maximize
the health of the population from available resources.
With the rise of formularies, physicians grapple with
issues such as: determining best therapeutic choices based
on current evidence and clinical experience, and formu-
lary rules controlling third party payers' costs [1-6].
Most research in this area has relied on quantitative
approaches such as observational studies of prescription
drug claims data[7,8] to provide information on what
physicians prescribe, but are unable to provide insight
into physicians' attitudes about the prescribing process.
Qualitative methods are well suited to identify and
explore the complex decision-making processes physi-
cians experience when prescribing.
The Ontario Drug Benefit Program (ODBP)
The Government of Ontario manages a publicly-funded
prescription drug insurance plan for eligible beneficiaries.
The Ministry of Health and Long-term Care (MOHLTC)
provides coverage through the ODBP formulary for
patients who are over 65 years or who receive social assist-
ance. This formulary also applies to the ODBP's Trillium
drug program to which individuals apply for coverage for
prescription expenses in excess of a threshold amount rel-
ative to their income.
The MOHLTC established the formulary in 1974 in con-
sultation with the ministry's external expert drug advisory
committee, the Drug Quality and Therapeutics Commit-
tee (DQTC), that provides independent and specialized
advice to the Minister of Health and the Drug Programs
Branch on drug-related issues. The DQTC (now known as
the Committee to Evaluate Drugs) monitors and evaluates
the list of drugs available based on drug use patterns,
experience, and current scientific knowledge monthly. For
drug products to be eligible for consideration for listing in
the formulary, a drug manufacturer must provide a com-
plete submission in accordance with provincial drug leg-
islation. A complete submission undergoes a thorough
review using current therapeutic guidelines and evidence-
based data[9].
In June of 2006, Royal Assent was granted The Transparent
Drug System for Patients Act, 2006 that revised a number of
elements of the publicly funded insurance program fol-
lowing a comprehensive program review. The MOHTLC's
objectives for the ODBP reforms were: improving patient
access to drugs, ensuring better value for money, promot-
ing the appropriate use of drugs, rewarding innovations,
and strengthening transparency and accountability[10].
This article describes the three levels of drug coverage and
the associated administrative burden on physicians as
they existed in 2002, prior to the reforms. Under the first
ODBP level of coverage, physicians could prescribe gen-
eral benefit (GB) drugs without consulting reimburse-
ment criteria. When drugs are available from multiple
manufacturers, however, the ODBP required pharmacists
to dispense products with the lowest listed prices. The sec-
ond level of coverage permitted physicians to prescribe
Limited Use (LU) drugs. LU prescriptions required precise
eligibility codes that justified LU drugs for treatment of
predefined conditions under restricted circumstances. LU
prescriptions required physicians to handwrite and sign
prescriptions using special ministry-supplied prescription
pads. The prescriptions were valid for one year from the
signing date.
A third level of ODBP coverage applied to drugs not listed
as benefits. Drugs may not be listed on the ODBP if the
DQTC finds the evidence has not shown them to be effec-
tive or safe for the patient population that is covered by
the Ontario public plan. These drugs may be made avail-
able under special circumstances i.e., "to treat conditions
or diseases that would otherwise cause severe debilitating
effects"[9] to patients who are unable to benefit from any
of the drugs listed by the ODBP (GB or LU), or who do not
meet the strict LU drug eligibility criteria[11]. For coverage
to be granted for unlisted drugs, physicians had to care-
fully document a clinical description and therapeutic plan
and other information for reimbursement under the Indi-
vidual Clinical Review Mechanism (Section 8) of the
ODBP. Medical experts contracted by the MOHTLC
reviewed the request and advised physicians if coverage
was approved. Under the regulations in place in 2002,
coverage had to be renewed annually. A full description of
this mechanism is available in Part VIII of the formu-
lary[9].
The objective of this qualitative study was to examine fam-
ily physicians' attitudes toward restrictions on prescrip-
tion reimbursement through the ODBP and how this
influences their prescribing practices. Physicians articu-
lated that formulary requirements exacerbate existing ten-
sions in clinical practice. This study, however, does not
provide a definitive evaluation of the consequences of
reimbursement criteria nor does it compare and contrast
systems. Rather, it more fully explores the attitudes of
physicians in relation to the public drug insurance pro-
gram in Ontario as it was structured in 2002, and expands
on physicians' sentiments to suggest that additional
research is needed to determine how formulary manage-
ment practices may impact patient outcomes[12].BMC Family Practice 2009, 10:69 http://www.biomedcentral.com/1471-2296/10/69
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Methods
Participants
Using purposive sampling, family physicians from four
cities in Southern Ontario were recruited to participate in
one of six focus group sessions in this exploratory qualita-
tive study. In cooperation with the researchers, recruit-
ment was conducted by Pollara, a national public and
private research firm. For the purposes of this study, Pol-
lara contacted physicians who met practice-type eligibility
criteria with the intent to find a sample of Ontario family
physicians. Physicians were drawn from larger and
smaller cities (population range: 2.4 million to 74 thou-
sand), and were in full-time family practice in either pri-
vate practice, academic or non-academic hospital settings.
Physicians recruited had active practice experience that
ranged from  10 years to  10 years, and experience in
caring for patients > 65 years of age.
A total of 51 physicians agreed to participate and 48
attended the sessions. Eighty percent of the physicians
were in private practice with 10% of the remainder prac-
ticing in academic and non-academic hospital settings,
respectively. Most of the physicians were male 69% (n =
33), which approximates Ontario's family physician gen-
der ratio, 100% were in clinical practice more than 80% of
their time, and 85% had been in practice for more than 10
years. Their practice populations included 10 - 75% of
patients over the age of 65 (mean = 36%). Having experi-
ence prescribing for seniors is important given persons 65
years of age and over are the largest group of beneficiaries
under the ODBP. A $200.00 (Canadian) incentive was
provided. In this focus group research, sample size was
estimated by aiming for 6-8 persons per group with a base
of 3-4 groups or more until theoretical saturation and
information richness was reached[13].
Ethics approval was received for this study from McMaster
University's Hamilton Health Sciences/Faculty of Health
Sciences Research Ethics Board (REB).
Focus Groups
Focus group questions were developed and pre-tested by
the investigators with five physicians who were represent-
ative of the study population. Six focus groups were con-
ducted over a two week period in December 2002 with an
average of eight physicians per focus group. Sessions aver-
aged two hours in length and were led by a trained focus
group facilitator.
At the start of each focus group, the facilitator explained
the purpose of the session and asked physicians to sign a
statement of informed consent. Once those were signed,
physicians were presented with two of four possible clini-
cal practice scenarios describing conditions commonly
managed by family physicians (see Table 1). The patients
in the scenarios were either ODBP beneficiaries or self-pay
or private insurance beneficiaries. Medications that might
be prescribed included those available as a GB or through
LU or section 8 processes. The two scenarios were
intended to situate the participants in a patient encounter
leading to a prescribing decision; thus, they were asked to
quietly read each scenario and write a mock prescription.
The moderator then used semi-structured and open-
ended questions to facilitate interaction and guide partic-
ipants through a discussion of their decision-making
process when prescribing and attitudes about their pre-
scribing decisions.
In the osteoarthritis scenario the clinical history suggested
that gastrointestinal protection should be considered in
the event a non-steroidal anti-inflammatory drug was
chosen. Coxibs, an LU product, were a possible choice but
there were safety and efficacy data in the public domain
that was stimulating debate about their place in therapy.
Table 1: Clinical practice scenarios employed to situate focus group sessions
Condition Presentation
Asthma A 35 year old asthmatic woman has recently moved into subsidized housing where there are cats. One year ago she had a 
normal spirometry but has recently experienced coughing, and dyspnea with wheezing and disturbed sleep. She inhales 
budesonide daily and has increased her use of terbutaline with the recent increase in symptoms. She is reluctant to increase her 
us e of corticosteroids.
Hypertension A 55 year old male has type 2 diabetes that is currently managed with diet and exercise. Physical exam, ECG, BMI, and renal 
function are normal. Lipid levels are not at recommended targets per the CCS guidelines and repeated BP readings indicate mild 
to moderate hypertension.
Osteoarthritis A 41 year old female began to have right hip pain four years ago that progressed to both hips and knees. Three months of 
acetaminophen was ineffective for pain relief; naproxen caused dyspepsia and a positive occult blood stool sample. Her smoking 
cessation efforts (pack-a-day) resulted in weight gain that exacerbated her joint pain. Pain is now daily and may force a job 
change if not controlled.
Osteoporosis A 75 year old male has become progressively more stooped and experienced episodes of back pain over the past 6 months. 
Densiometry revealed a BMI > 2 SD below the mean for young men and a serum testosterone level on the low end of normal. 
He has now suffered a fractured wrist in an accidental fall.BMC Family Practice 2009, 10:69 http://www.biomedcentral.com/1471-2296/10/69
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Proton pump inhibitors, in combination with traditional
non-steroidal anti-inflammatory drugs, were also recom-
mended by existing guidelines and these were also agents
that required an LU prescription for ODBP beneficiaries.
The osteoarthritis scenario was included in each focus
group session because our earlier research[14] confirmed
that general practitioners made different osteoarthritis
management choices (3 different prescribing behavior
types) depending on the patient's insurance status. How-
ever, the medications actually chosen by the participants
in response to each scenario were not the focus of the
research and were relevant only in so far as they stimu-
lated discussion among the participants on prescribing
choice and attitudes towards prescribing.
Analysis
Focus group recordings were transcribed and verified
against the original recordings. A set of preliminary cod-
ing categories based on the key questions and content of
the data collected were created and then refined and
sorted into sub-themes with the assistance of NVivo soft-
ware. Two researchers independently coded the tran-
scripts and discussed their emergent themes to reach
consensus. Content validity was supported through the
emergence of substantively similar perspectives held by
physicians across the focus groups. Using these themes we
describe the common steps of the decision-making proc-
ess and factors influencing prescribing behavior. It should
be noted that focus group responses constitute self-reports
and may not predict actual physician behavior in patient
consultations.
Results
Influence of reimbursement guidelines on prescribing
Physicians reported that during the clinical consult they
diagnose and assess concomitant conditions such as
social and environmental factors, prior treatment history,
risks for adverse events including comorbidity and, if drug
therapy is chosen, possible drug interactions. Most physi-
cians in this study, unlike their counterparts elsewhere,
explained that they review with patients their ability to
pay for medications [15-17]. When most physicians dis-
covered that a patient was over the age of 65 years,
received professional services under the home care pro-
gram, or received social assistance, prescribing decisions
based on the reimbursement guidelines of the ODBP
came into play.
Prescribing General Benefit (GB) Drugs
Physicians noted that GB drugs are generally well toler-
ated and effective. However, some participants perceived
that current evidence and clinical experience may run con-
trary to ODBP guidelines in which multiple-source GB
drugs are classified as interchangeable. Participants noted
that while GB drugs are commonly viewed as un-
restricted, they are not always "hassle-free", and require
formulary consultation for dosage compliance and special
forms if a "non-substitution" order is required.
Some physicians reported that, despite it not being their
first choice, they might still prescribe a GB drug for a vari-
ety of reasons: a) the GB drug is covered, thus the patient
could get medication immediately, b) the patient's symp-
toms were not acute at the time of presentation, c) a trial
of the GB drug might be effective in improving the
patient's condition, d) the GB drug, while not the most
effective drug in the physician's opinion, was safe and
effective and did no harm, e) the desire to balance quality
of care with fiscal restraint, f) if the patient experienced
side-effects or the GB drug proved ineffective then the
patient's chart would contain the necessary proof that a
GB drug was tried and the patient could then meet the LU
coverage criteria, and g) the GB drug was a stopgap to be
used while awaiting the lengthy Section 8 approval proc-
ess.
Prescribing Limited Use (LU) Drugs
Physicians see their primary responsibility - providing the
best possible care for patients - as "covenantal"[18]. They
find it worrisome when patients do not precisely fit the LU
eligibility criteria, especially when clinical experience,
interpretation of the evidence, and patient history make a
convincing case for an LU drug. One physician explained
that, "it's almost clinical malpractice to give him [the patient]
the drug that's free, knowing there is no efficacy, OK?" Physi-
cians see themselves as duty-bound to fulfill their primary
responsibility to patients, but realize that health care costs
are rising and that potential legal and financial penalties
loom if they are in contravention of ODBP regulations.
Individual Clinical Review (Section 8) mechanisms and 
prescribing
"Section 8" refers to the "Individual Clinical Review
Mechanisms" section of the ODBP Formulary. It is used
when ODBP-eligible patients either may benefit from LU
drugs but do not fit the criteria or when they require drugs
not listed as GB or LU. Physicians must send a written
request for Section 8 review to the Drug Programs Branch
of the MOHLTC. Ministry staff coordinates a review that
includes recommendations from the DQTC and expert
medical advisors. Written requests must provide a diagno-
sis and rationale for the drug, its trade name, strength and
dosage, evidence of effectiveness if the patient has already
taken the product, details of alternatives tried including
dosages, length of therapy and patient response. Concom-
itant drug therapy and other relevant information, such as
sensitivity reports or laboratory results, are also
required[19].BMC Family Practice 2009, 10:69 http://www.biomedcentral.com/1471-2296/10/69
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A decision to access Section 8 represents a commitment to
writing multiple letters annually to maintain coverage as
extensions are not automatic. In cases where the coverage
is approved but the dosage changes, a new request must
be completed. Some physicians reported that it could take
up to four attempts to get a drug covered. It is relatively
common to be turned down on the first try.
Advocating for ODBP-eligible patients
We identified three themes associated with physician
advocacy: issues related to time, physician frustration and
burnout, and physician-patient rapport. The dominant
theme relates to issues of time.
Issues related to time
Physicians believe that already they do not have enough
time with patients and coping with ODBP regulations
aggravates this problem. One physician noted, "I don't
book my patients that tight together. I give them their 15 min-
utes. But my goodness, you know, I consider that my 15 min-
utes [are] for diagnosis and a treatment plan, not to handle
bureaucracy and it gets really frustrating." Other time issues
include: a) time to review patient charts for reimburse-
ment eligibility, b) time to interpret the ODBP guidelines
and write compliant prescriptions, c) non-billable time
for telephone calls with pharmacists, dealing with reim-
bursement problems or writing Section 8 letters, and d)
time spent waiting for Section 8 approval. There is the per-
ception that the prescribing process is deliberately made
complex and time-consuming to ensure guideline compli-
ance and that this interferes with timely delivery of quality
healthcare.
Physicians noted that they must use non-billable time
(usually at the end of the day) to write and fax paperwork.
"Now they [ODBP]don't have a 1-800 number if you want to
fax so you have to call and wait in line at your own expense for
the patient or you have to send it by registered mail as if you
have nothing better to do then spend time, at least half an hour,
to compose a letter, do it right for the government and then at
our own expense, getting it there and wait for rejection and you
know, there are a lot of barriers." Some physicians also per-
ceived an expectation that they complete LU prescriptions
and Section 8 letters for specialists that their patients also
visit.
Frustration with the ODBP Program
Physicians generally perceived ODBP guidelines as disin-
centive hoops, and saw themselves being used as free
watchdog gate-keepers to monitor drug costs. They
thought that strict adherence to ODBP guidelines might
cut drug costs, but could create ancillary costs through
poor use of physicians' time and burdening other sectors
of the system (i.e., emergency room visits). Most physi-
cians perceive the formulary as complicating rather than
facilitating clinical decisions. Words such as "red tape",
"hoops", "barriers", and "bureaucracy" were commonly
used to describe their experience with the ODBP. In addi-
tion, it was common to hear physicians note that they
were not confident in the formulary's ability to reflect cur-
rent evidence or clinical experience.
Physician "burn-out"
In general, physicians perceived that the ODBP processes
seem to have been created to wear down family physi-
cians. They identified the cumbersome 500-page formu-
lary binder, rigid dosages, changing LU codes, complex
regulations and long waits for approval (three weeks to
three months) as daily hurdles on the ODBP obstacle
course. While most physicians reported that they contin-
ued to advocate for patients amid frustrations, for some,
the daily burden of coping with ODBP barriers resulted in
them becoming disheartened and taking the path of least
resistance. These physicians could be termed "discouraged
advocates"; they surrender and prescribe the GB drug.
Physicians reported that they may want to comply with
the stepped care approach, (i.e., trying a GB drug and then
following all steps needed to access restricted drugs in the
event of treatment failure), but they have many patients
requiring advocacy and thus are spending more time
"jumping through hoops" than providing quality care.
"The frustrating thing, which I think all of us could probably
attest to, is that we're the ones always holding the bag, because
in the end, patients get all kinds of red tape but the family phy-
sician has to wade through all of it." Some physicians
reported that the ministry's inconsistent application of
Section 8 guidelines eroded their confidence in the system
and their ability to successfully advocate for patients.
Physician/Patient Rapport
Despite these obstacles, physicians say they advocate
because they care about their patients and feel that they
are morally and legally bound to provide them with the
best care. One physician summed up the common thread
heard from most physicians: "We could say, 'no, sorry, there
is nothing that I can do,' but we care." Physicians admit that
the rapport that grows between patients and physicians
can influence their decision to go the extra distance, but it
is not a requirement. Having patients who appreciate their
advocacy encourages physicians to continue to do so.
Committing to a patient's case is time consuming over the
long and short haul, and requires tenacity and a convic-
tion of the restricted-access drug's efficacy.
Factors that influence family physicians' decisions not to
advocate fall into two categories relating to patients'
attributes and the working conditions and policies associ-
ated with practicing medicine. Physicians noted that they
tend to advocate more actively for patients who do not
have the income to pay for non-covered drugs. They areBMC Family Practice 2009, 10:69 http://www.biomedcentral.com/1471-2296/10/69
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disinclined to advocate for patients who have a strong a
sense of entitlement even when they can pay or those who
pay for expensive alternative/complementary therapies of
dubious benefit but resist paying for a more effective but
non-covered medication.
Some physicians reported that they typically avoid con-
sulting the ODBP formulary when writing prescriptions
except in extreme circumstances. The most common rea-
son given is that the formulary was not usually in the
examination room and/or referring to it is onerous and
consumes precious consultation time with their patients.
Some physicians explained that they write prescriptions
for drugs and let the pharmacist research, screen and sort
out the ramifications regarding ODBP coverage. The gen-
eral trend in responses from these physicians is that they
see their responsibility as primarily caring for their
patients rather than implementing cost-containment
strategies on behalf of the provincial government. In situ-
ations where a patient's need was acute, these discouraged
advocates would advocate for the patient to receive cover-
age, but they appear to struggle with taking a proactive
stance.
Discussion
Formulary-based public drug plans extend health cover-
age for most financially disadvantaged populations and,
in some Canadian provinces, for their citizens as a whole.
The formulary review process that is part of every public
drug plan in Canada assesses each new drug for safety,
efficacy, and cost-effectiveness. This provides physicians
with some assurances of the composite value of those
drugs that do get listed on the formulary. While physi-
cians in this study generally agreed that cost-effectiveness
is a worthy goal, they did not generally see their role as
cost monitors. With respect to their experience with the
ODBP as it was structured in 2002, they felt it would be
more effective if it more accurately reflected standard clin-
ical practice and current clinical guidelines and was less
complicated to administer. Physicians also argued that,
while the ODBP should ideally contribute to the improve-
ment of the quality of care and keep costs down, it can
also contribute to lower quality of care and to the misuse
of physicians' time thereby increasing costs to the pub-
licly-funded health care system in Ontario by adding
unnecessary visits to family physicians, specialists, and
emergency rooms.
Data from this relatively small qualitative study suggests
that advocacy is situationally bound. While we learned
that physicians' decisions to advocate are influenced by
their understanding of the patient's condition, the level
and immediacy of risk created by the patient's condition,
and the perceived benefit of a restricted drug, we discov-
ered that their decision to advocate is also influenced by
having the necessary time, stamina, conviction, and
encouragement. These findings are similar to those of
other published literature[20,21]. Findings reveal that the
ODBP regulations of 2002 were seen by these physicians
as complex and onerous and had a substantial impact on
the physician-patient relationship and on patient out-
comes. The findings and conclusions of this preliminary
study also find resonance in the Ontario Medical Associa-
tion's response to the Drug Strategy Review (DSR) that
preceded the recent reforms to the ODBP: "When consid-
ering the LU and Section 8 processes the DSR Steering
Committee should not underestimate the depth and
intensity of physician enmity to these programs"[22].
When reimbursement hurdles remain difficult and
numerous, there will be some physicians who will
become worn down. The result is that reimbursement
guidelines can influence medication choice and can pro-
duce unequal access to medication.
Conclusion
This study provides an understanding of family physi-
cians' attitudes about prescribing under the ODBP formu-
lary as it was designed in 2002. At that time, these family
physicians were concerned about the impact of the ODBP
formulary on patient outcomes, the loss of their diagnosis
and treatment time due to drug coverage paperwork,
whether some generic drugs were as effective as name-
brand counterparts, and the lengthy wait times for drug
coverage that they felt could put some patients at risk.
These concerns were addressed in 2006 when the provin-
cial government passed legislation to overhaul the ODBP
to increase overall transparency and accountability, estab-
lish faster drug funding decisions, assess the administra-
tive barriers of the Section 8 mechanism, and replace it
with a new faster process with the intention of dramati-
cally reducing paperwork for physicians and pharma-
cists[23].
Allan and Innes report that Canadian physicians in British
Columbia have limited knowledge of the actual price of
drugs[24]. However, physicians do know that if a drug is
not included in a formulary it is likely to be more costly
than formulary alternatives[24]. It may be that the oner-
ous nature of the old ODBP guidelines actually precipi-
tated physicians asking about coverage and ability to pay
because they were attempting to determine if they would
require additional time to complete paperwork. Alterna-
tively, physicians could be responding to a social desira-
bility factor.
While the focus of this qualitative study was not family
physicians' knowledge of drug costs but on their attitudes
about prescribing using a formulary, we learned that these
family physicians' knowledge of relative costs of drugs is
based on their experience that formularies list less costlyBMC Family Practice 2009, 10:69 http://www.biomedcentral.com/1471-2296/10/69
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generic or brand-name drugs and not newer more expen-
sive ones. Family physicians reported that they learned the
costs of drugs through daily clinical practice, especially
when their patients returned to report the high price of a
drug they prescribed or when pharmacists called saying
their patients weren't covered or couldn't afford a drug.
Reports of formulary inclusion decisions indicate that the
coverage decision can be sensitive to the price of a medi-
cation [25,26]. In their analysis of 58 drugs approved for
sale in Canada in 1996-1997, Anis et al[25] found a sig-
nificant association (p < .001) between the price ratio
(price of the new drug relative to price of the cheapest
available comparator on the formulary) and whether cov-
erage was granted.
Study Limitations and directions for future research
The findings from this preliminary study cannot be gener-
alized to physicians practicing in other provinces or coun-
tries, or Ontario physicians practicing under the new
ODBP regulations. Our findings differ substantially from
US data regarding the practice of family physicians asking
patients about their ability to pay. It may be that adminis-
trative hurdles actually precipitate physicians asking and
is an attempt to gauge the impact of embarking on patient
advocacy in relation to the themes described in this study.
The relative influence of a social desirability factor could
not be determined from our results. Moreover, it is possi-
ble that some physicians in this study lacked full and accu-
rate information in some aspects of the ODBP, and this
could have influenced their discussion. Nonetheless, their
comments are still valid, as they are making prescribing
decisions for their patients with this limited understand-
ing. Future research, possibly with a larger sample using a
survey instrument designed around the themes uncovered
in this study, might prove valuable. In addition, Allen,
Lexchin and Wiebe argue that understanding the accessi-
bility and reliability of medical cost information provided
to physicians and whether physicians use that informa-
tion and prescribe differently as a result are important top-
ics to be explored[27].
It emerged from this study that physicians have concerns
about the impact of drug substitution or delays in obtain-
ing drugs on patient outcomes, and more research is
required to explore these concerns. Given the administra-
tive reforms recently enacted in the ODBP, it would be
worthwhile to replicate and enlarge on this research to
examine whether or not physicians' attitudes and pre-
scribing practices have changed especially in light of new
ODBP changes. Applying the structured inquiry described
here to the new prescribing context in order to compare
and contrast results would provide a rare opportunity to
measure the impact of specific aspects of drug plan policy.
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